A Study to Identify Breast Cancer (IDBC) (NCT04495244)
Investigation of a Novel Blood Test to Identify Breast Cancer (IDBC)
🩺 Plain-English Summary (8th-Grade Level)
Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed. The primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics.
Who can join: Review the eligibility criteria below.
Location: Alberta Cancer Research Biobank — Calgary, Alberta
Age range: 30 Years to 75 Years
🧪 Interventions in This Study
- Syantra DX Breast Cancer (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Alberta Cancer Research Biobank — Calgary, Alberta
- Severance Hospital — Soeul,
- North Manchester General Hospital — Manchester,
- Wythenshawe Hospital, Southmoor Road — Manchester,
📞 Contact the Study Coordinator
Phone: 0161 291 4045
Email: Natasha.Jones@mft.nhs.uk
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer Female
- Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer — Tampa, Florida
- Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial — Phoenix, Arizona
- Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer — Charlottesville, Virginia
- Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women — Aurora, Colorado
- Assessment of Breast Cancer Patients Satisfaction and Health Related Quality of Life Outcomes — Detroit, Michigan
- Robotic vs. Open NSM for Early Stage Breast Cancer — Irvine, California
Explore by condition: All Breast Cancer Female clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.